Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Cash & Equivalents	3.95	0.38	5.14	14.06	1.93
Cash & Short-Term Investments	3.95	0.38	5.14	14.06	1.93
Cash Growth	950.04%	-92.69%	-63.45%	628.97%	2036.87%
Other Receivables	-	-	-	-	0.02
Receivables	-	-	-	-	0.02
Prepaid Expenses	0.23	0.08	0.69	0.35	0.97
Total Current Assets	4.18	0.46	5.84	14.41	2.91
Property, Plant & Equipment	0.43	0.18	0.08	0.1	-
Total Assets	4.6	0.63	5.92	14.52	2.91
Accounts Payable	0.63	2.93	2.87	1.16	0.5
Short-Term Debt	-	0.3	-	-	0.34
Other Current Liabilities	-	-	-	0	0.06
Total Current Liabilities	0.63	3.23	2.87	1.16	0.9
Total Liabilities	0.63	3.23	2.87	1.16	0.9
Common Stock	0	0	0	0.01	0.01
Additional Paid-In Capital	62.5	51.43	62	57.42	33.72
Retained Earnings	-58.54	-54.02	-44.07	-29.19	-16.83
Comprehensive Income & Other	-	-	-14.88	-14.88	-14.88
Total Common Equity	3.97	-2.59	3.05	13.35	2.01
Shareholders' Equity	3.97	-2.59	3.05	13.35	2.01
Total Liabilities & Equity	4.6	0.63	5.92	14.52	2.91
Total Debt	-	0.3	-	-	0.34
Net Cash (Debt)	3.95	0.08	5.14	14.06	1.59
Net Cash Growth	5141.53%	-98.53%	-63.45%	782.32%	5671.48%
Net Cash Per Share	8.76	1.00	71.17	213.10	29.62
Filing Date Shares Outstanding	2.9	0.09	0.07	0.07	0.06
Total Common Shares Outstanding	0.78	0.08	0.07	0.07	0.05
Working Capital	3.54	-2.77	2.97	13.25	2.01
Book Value Per Share	5.10	-33.94	42.41	188.78	40.30
Tangible Book Value	3.97	-2.59	3.05	13.35	2.01
Tangible Book Value Per Share	5.10	-33.94	42.41	188.78	40.30

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q